drug
MIFEPRISTONE
Marketedupdated 3mo agoby $CORT CORCEPT THERAPEUTICS INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(6)
approval · 6
Apr 11, 2019
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
May 14, 2021
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Jan 3, 2023
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Mar 23, 2023
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Sep 30, 2025
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Sep 30, 2025
approval
MIFEPRISTONE — FDA approval
MIFEPRISTONE
→
Trials studying MIFEPRISTONE
- phase2A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- —Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion
- phase4Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
- phase2RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Trauma
- phase2REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism
- phase2Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 27, 2028
~2.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (18)
- Aug 22, 2038method-of-use (U-1643)US 10231983
- Aug 22, 2038method-of-use (U-1643)US 10314850
- Aug 22, 2038method-of-use (U-1643)US 10780097
- Jun 19, 2037method-of-use (U-1643)US 10195214
- Jun 19, 2037method-of-use (U-1643)US 10842800
- Jun 19, 2037method-of-use (U-1643)US 11969435
- Jun 19, 2037method-of-use (U-1643)US 12097210
- Jan 18, 2037method-of-use (U-1643)US 10151763
- Aug 15, 2036method-of-use (U-1643)US 9829495
- Aug 12, 2036method-of-use (U-1643)US 10006924
- Aug 12, 2036method-of-use (U-1643)US 10495650
- Apr 20, 2036method-of-use (U-1643)US 10166242
- Apr 20, 2036method-of-use (U-1643)US 10166243
- Apr 20, 2036method-of-use (U-1643)US 10660904
- Apr 20, 2036method-of-use (U-1643)US 9943526
- Mar 5, 2033method-of-use (U-1643)US 10500216
- Nov 15, 2032method-of-use (U-1643)US 10842801
- Aug 27, 2028method-of-use (U-1643)US 89213482.0y
News(10)
- Virginia federal judge says FDA should reconsider mifepristone restrictionsAt a time when the federal government is evaluating restrictions on medication abortion, a federal judge determined that the last administration imposed too many. A Virginia federal judge ordered t…endpoints · 18d ago
- Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challengeA group of 61 biopharma companies, executives and investors has filed an amicus brief in support of the FDA in an ongoing case brought by Louisiana meant to remove access to the abortion pill mifep…fiercebiotech · 24d ago
- A renewed push from the right against abortion pillsThe latest on cyclospora, THC sodas at the grocery store, and more health news from Morning Roundsstat · 24d ago
- STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and moreDrugmakers and patient groups asked the FDA to pause former commissioner Marty Markary's National Priority Voucher drug review programstat · 2mo ago
- The latest on Ebola: A travel ban and an old vaccineAffordable Care Act changes, drinking while pregnant, and more health news from Morning Roundsstat · 2mo ago
- Texas is opening up a detransition clinicAmericans exposed to Ebola outbreak, Bill Cassidy's primary defeat, and more health news from Morning Roundsstat · 2mo ago
- Opinion: How to restore credibility to the CDC’s vaccine advisory committeeJesse Goodman, former director of CBER and former FDA chief scientist, calls for five critical changes to restore trust in the Advisory Committee on Immunization Practices.stat · 2mo ago
- Opinion: ‘Patient autonomy’ has nothing to do with childhood vaccine policiesOpinion: Vaccine policy it is not a matter of autonomy at all, because infants do not decline vaccination — their parents do.stat · 2mo ago
- Opinion: The cloudy truth about ‘blue zones’“There's been interest in longevity, promoting it, for millennia. But this 25-year campaign really brought it to the forefront,” Eric Topol says of blue zones.stat · 3mo ago
- Opinion: Marty Makary misunderstood something fundamental about the FDA“The norm-shattering masks a more fundamental misunderstanding of how administrative power can bring about lasting change,” writes Joshua Sharfstein.stat · 3mo ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that